Not too long ago, “special populations” of hepatitis C infection referred to patients failing to achieve SVR with the currently available DAA therapies. Now, as therapeutic efficacy has progressed, the concept of special populations has shifted focus to include treatment of people affected by HCV-related hepatic and extrahepatic manifestations.
In this issue, Dr. Paul Martin and Dr. Kalyan Ram Bhamidimarri of the University of Miami analyze recent publications on managing HCV complications in special populations — patients with chronic kidney disease, cryoglobulinemia, cirrhosis, and HIV coinfection, and those receiving transplant organs from HCV-infected donors.
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: September 28, 2018
Expiration date: September 27, 2020